G2gbio KRX:456160KOSDAQ
지투지바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h4
Articles, 7 days6
DART filings, 7 days2
Articles tracked6since Sep 11
In Q2 2026, G2gbio reported revenue of ₩1.6bn, up 944.7% year on year, and an operating loss of ₩2.7bn. G2gbio (지투지바이오) appeared in 6 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 15 with 3 articles. It was most often mentioned alongside BioInfra.
G2gbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.6bn | +944.7% | −₩2.7bn | −₩5.7bn |
| Q1 2026 | ₩351m | +4364.3% | −₩3.3bn | −₩5.5bn |
| Q4 2025 derived | ₩203m | – | −₩3.0bn | −₩2.8bn |
| Q3 2025 | ₩58m | -71.0% | −₩3.6bn | −₩3.5bn |
| Q2 2025 | ₩153m | +90.0% | −₩2.7bn | −₩2.9bn |
| Q1 2025 | ₩8m | -98.4% | −₩2.9bn | −₩2.9bn |
| Q4 2024 derived | −₩2m | -100.3% | −₩3.3bn | −₩3.2bn |
| Q3 2024 | ₩202m | +941.4% | −₩2.8bn | −₩2.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
G2gbio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
